Pinostrobin pentanoate as a selective estrogen receptor-α antagonist in breast cancer: integrated in silico and in vitro evaluation
Research in Pharmaceutical Sciences · 2026-07 · 21 (4) · 466-480
DOI: 10.4103/rps.rps_108_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research in Pharmaceutical Sciences, online erschienen am 27.07.2026. Verfasst von Tri Widiandani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and purpose: Breast cancer remains the most commonly diagnosed cancer and the leading cause of cancer-related death among women worldwide. Estrogen receptor alpha (ERα) plays a major role in breast cancer cell proliferation, and approximately 70-80% of breast cancer cases are classified as Erα-positive. This study aims to predict the pinostrobin pentanoate potential against ERα by docking and molecular dynamics, and determine its cytotoxic activity against T47D breast cancer cells and normal cells. Experimental approach: Docking was analyzed using MOE 2022.02. Furthermore, AMBER 20 was used for molecular dynamics. Cytotoxicity was assessed using the MTT assay against T47D breast cancer cells and Vero cells for its selectivity index (SI). Findings/Results: Based on docking results, the binding free energy of pinostrobin pentanoate (-7.682 ± 0.145 kcal/mol) was lower compared to pinostrobin (-6.503 ± 0.153 kcal/mol) against ERα, indicating the stronger binding affinity. In addition, the stability interaction using 100 ns molecular dynamics showed a stable interaction. Moreover, the IC 50 values of pinostrobin and pinostrobin pentanoate against T47D cells were 160 ± 5.30 μM and 32 ± 3.64 μM, respectively, compared to doxorubicin 0.14 ± 0.04 μM. Meanwhile, the CC 50 values of pinostrobin and pinostrobin pentanoate from the cytotoxicity test on Vero cells were estimated to be > 2500 and > 1500 μM, respectively. Therefore, the SI value of pinostrobin (SI > 15.6) is estimated to be smaller than that of pinostrobin pentanoate (SI > 46.8). Additionally, the combination of pinostrobin pentanoate and doxorubicin showed synergistic efficacy. Conclusion and implications: Pinostrobin pentanoate is more selective than pinostrobin, and it can be used as an anti-breast cancer candidate against the ERα for further research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia.
- Research Group of Drug Development, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia.
- Inter-University Center of Excellence (IUCoE) of Health Autonomy-Drug Discovery, Universitas Airlangga, Surabaya 60115, Indonesia.
- Master Program of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia.
- Department of Pharmacy, Faculty of Sports and Health, Universitas Negeri Gorontalo, Gorontalo 96128, Indonesia.
- Faculty of Pharmacy, Institut Ilmu Kesehatan Bhakti Wiyata, Kediri 64114, Indonesia.
Zitieren
APA
Widiandani, T., Susilawati, D., Rahman, A., Rahmah, S., Sulistyowaty, M. I., Suryadi, A. M. A., Purwanto, B. T., & Siswodihardjo, S. (2026). Pinostrobin pentanoate as a selective estrogen receptor-α antagonist in breast cancer: integrated in silico and in vitro evaluation. Research in Pharmaceutical Sciences, 21(4), 466-480. https://doi.org/10.4103/rps.rps_108_25
Vancouver
Widiandani T, Susilawati D, Rahman A, Rahmah S, Sulistyowaty MI, Suryadi AMA, et al. Pinostrobin pentanoate as a selective estrogen receptor-α antagonist in breast cancer: integrated in silico and in vitro evaluation. Research in Pharmaceutical Sciences. 2026;21(4):466-480. doi:10.4103/rps.rps_108_25
BibTeX
@article{Widiandani2026,
author = {Widiandani, Tri and Susilawati, Delis and Rahman, Ave and Rahmah, Siti and Sulistyowaty, Melanny Ika and Suryadi, A Mu'thi Andy and Purwanto, Bambang Tri and Siswodihardjo, Siswandono},
title = {Pinostrobin pentanoate as a selective estrogen receptor-α antagonist in breast cancer: integrated in silico and in vitro evaluation},
journal = {Research in Pharmaceutical Sciences},
year = {2026},
volume = {21},
number = {4},
pages = {466--480},
doi = {10.4103/rps.rps_108_25}
}
EUVIMED